Partnership with Eurofins Explored by Graft Polymer UK CEO in PTSD Treatment Context

October 04, 2024 08:09 PM AEST | By Team Kalkine Media

Google News:

Partnership with Eurofins Explored by Graft Polymer UK CEO in PTSD Treatment Context — Image source: Shutterstock

Recent News

Impact Minerals Charts Long-Term HPA Future with Lake Hope Project, Ba...

Woolworths and Transurban: Underperforming Stocks on the ASX Radar

Vanadium Resources Fast-Tracks Steelpoortdrift Project with Strategic...

Uranium Stocks Surge on ASX 200 Amid Oil Price Retreat

Highlights

Graft Polymer (UK) PLC is advancing a preclinical program focused on mental health conditions, particularly post-traumatic stress disorder (PTSD), in collaboration with Eurofins Discovery.
The company is testing its co-lead aminoindane series, designed to interact with serotonin, dopamine, and norepinephrine receptors to mitigate the human response to trauma.
CEO Anthony Tennyson emphasized the significant unmet need in PTSD treatment, noting that there are approximately 13 million sufferers in the U.S. alone, and Graft Polymer anticipates preclinical results by the end of November.

In a recent discussion with Proactive’s Stephen Gunnion, Graft Polymer (UK) PLC {LSE:GPL} CEO Anthony Tennyson highlighted the company's promising preclinical program aimed at addressing mental health conditions, specifically post-traumatic stress disorder (PTSD). Collaborating with Eurofins Discovery, Graft Polymer is currently evaluating its co-lead aminoindane series, a novel class of compounds that target serotonin, dopamine, and norepinephrine receptors to potentially alleviate trauma responses.

Tennyson noted the pervasive impact of PTSD, stating, “Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone.” He emphasized that existing treatment options are limited, creating a substantial addressable market for effective solutions. The partnership with Eurofins Discovery, known for its expertise in research services, is expected to expedite the development process, positioning Graft Polymer to make significant advancements in PTSD treatment.

The company is optimistic about the preclinical results, which are anticipated by the end of November. This timeline suggests a rapid progression in their research efforts, potentially paving the way for novel therapeutic approaches to combat PTSD and improve the quality of life for millions affected by this condition. Graft Polymer’s focus on addressing such an unmet need underscores its commitment to innovation in mental health treatments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.